Sunshine Biopharma Inc. (SBFMW)
Sunshine Biopharma Statistics
Share Statistics
Sunshine Biopharma has 10.1M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 10.1M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | 3.37% |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 64 |
| FTD / Avg. Volume | 0.37% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.41 and the forward PE ratio is null. Sunshine Biopharma's PEG ratio is 0.
| PE Ratio | -0.41 |
| Forward PE | n/a |
| PS Ratio | 0.06 |
| Forward PS | 0 |
| PB Ratio | 0.09 |
| P/FCF Ratio | -0.17 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Sunshine Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.11, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.11 |
| Quick Ratio | 2.33 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.18 |
| Debt / FCF | -0.08 |
| Interest Coverage | -662.43 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $670.66K |
| Profits Per Employee | $-98.73K |
| Employee Count | 52 |
| Asset Turnover | 1.14 |
| Inventory Turnover | 2.15 |
Taxes
| Income Tax | -234.86K |
| Effective Tax Rate | 4.37% |
Stock Price Statistics
The stock price has increased by 358.33% in the last 52 weeks. The beta is 0.38, so Sunshine Biopharma's price volatility has been higher than the market average.
| Beta | 0.38 |
| 52-Week Price Change | 358.33% |
| 50-Day Moving Average | 0.25 |
| 200-Day Moving Average | 0.16 |
| Relative Strength Index (RSI) | 52.59 |
| Average Volume (20 Days) | 17.09K |
Income Statement
In the last 12 months, Sunshine Biopharma had revenue of 34.87M and earned -5.13M in profits. Earnings per share was -7.32.
| Revenue | 34.87M |
| Gross Profit | 10.67M |
| Operating Income | -5.81M |
| Net Income | -5.13M |
| EBITDA | -5.15M |
| EBIT | -5.38M |
| Earnings Per Share (EPS) | -7.32 |
Balance Sheet
The company has 9.69M in cash and 952.48K in debt, giving a net cash position of 8.73M.
| Cash & Cash Equivalents | 9.69M |
| Total Debt | 952.48K |
| Net Cash | 8.73M |
| Retained Earnings | -69.04M |
| Total Assets | 30.56M |
| Working Capital | 19.65M |
Cash Flow
In the last 12 months, operating cash flow was -12.53M and capital expenditures 0, giving a free cash flow of -12.53M.
| Operating Cash Flow | -12.53M |
| Capital Expenditures | 0 |
| Free Cash Flow | -12.53M |
| FCF Per Share | -17.86 |
Margins
Gross margin is 30.6%, with operating and profit margins of -16.67% and -14.72%.
| Gross Margin | 30.6% |
| Operating Margin | -16.67% |
| Pretax Margin | -15.4% |
| Profit Margin | -14.72% |
| EBITDA Margin | -14.78% |
| EBIT Margin | -16.67% |
| FCF Margin | -35.93% |
Dividends & Yields
SBFMW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for SBFMW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -1.44 |
| Piotroski F-Score | 3 |